

Review

Adiponectin: An Attractive Marker for Metabolic Disorders in Chronic Obstructive Pulmonary Disease (COPD)

Andrea Bianco ^{1,†,*}, Gennaro Mazzearella ^{2,†}, Viviana Turchiarelli ¹, Ersilia Nigro ^{3,4},
Graziamaria Corbi ¹, Olga Scudiero ³, Matteo Sofia ⁵ and Aurora Daniele ^{3,4,6}

¹ Department of Medicine and Health Sciences, University of Molise, Via Giovanni Paolo II, Loc. Tappino, Campobasso 86100, Italy; E-Mails: viviana.turchiarelli@unimol.it (V.T.); graziamaria.corbi@unimol.it (G.C.)

² Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Via Leonardo Bianchi, Monaldi Hospital, Naples 80131, Italy; E-Mail: gennaro.mazzearella@unina2.it

³ CEINGE Biotechnologie Avanzate Scarl, Via Gaetano Salvatore 486, Naples 80145, Italy; E-Mails: nigro@ceinge.unina.it (E.N.); scudiero@ceinge.unina.it (O.S.); aurora.daniele@unina2.it (A.D.)

⁴ IRCCS–Fondazione SDN, Naples 80131, Italy

⁵ Department of Respiratory Medicine, AO Monaldi, University of Naples Federico II, Via Leonardo Bianchi, Monaldi Hospital, Naples 80131, Italy; E-Mail: matsouni@libero.it

⁶ Dipartimento di Scienze e Tecnologie Ambientali Biologiche Farmaceutiche, Seconda Università degli Studi di Napoli, Via Vivaldi 43, Caserta 81100, Italy

[†] These authors contributed equally to this work.

* Author to whom correspondence should be addressed; E-Mail: andrea.bianco@unimol.it; Tel.: +39-0874-409-263; Fax: +39-0874-404-752.

Received: 3 June 2013; in revised form: 18 September 2013 / Accepted: 23 September 2013 /

Published: 14 October 2013

Abstract: Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease which may be complicated by development of co-morbidities including metabolic disorders. Metabolic disorders commonly associated with this disease contribute to lung function impairment and mortality. Systemic inflammation appears to be a major factor linking COPD to metabolic alterations. Adipose tissue seems to interfere with systemic inflammation in COPD patients by producing a large number of proteins, known as “adipokines”, involved in various processes such as metabolism, immunity and inflammation. There is evidence that adiponectin is an important modulator of inflammatory processes

implicated in airway pathophysiology. Increased serum levels of adiponectin and expression of its receptors on lung tissues of COPD patients have recently highlighted the importance of the adiponectin pathway in this disease. Further, *in vitro* studies have demonstrated an anti-inflammatory activity for this adipokine at the level of lung epithelium. This review focuses on mechanisms by which adiponectin is implicated in linking COPD with metabolic disorders.

Keywords: COPD; adiponectin; metabolic disorders; adipose tissue

1. Introduction

There is a growing awareness that chronic obstructive pulmonary disease (COPD) is a lung disease not only restricted to pulmonary inflammation and airway remodeling [1]. Systemic effects and extrapulmonary comorbidities are common and significantly impact health outcomes in patients, including mortality. Cardiovascular diseases, musculoskeletal disorders, diabetes mellitus II and metabolic syndrome are among the most prevalent comorbidities; however the underlying molecular basis linking COPD and comorbidities are still not fully understood [2–4] although, in the last years, the relationship between comorbidities and systemic inflammation in COPD has been extensively analyzed. Whether systemic inflammation in COPD has been well recognized, the genesis of the systemic involvement needs to be further explored. It remains unclear whether systemic inflammation is the result of systemic diffusion of local inflammation in the lungs, or is a consequence of comorbid conditions which impact on lungs. Understanding how lung inflammation in COPD produces systemic consequences and interferes with co-morbidity development should be a priority.

Some evidence indicates that airway inflammation is mediated through a variety of cells, including macrophages, neutrophils, and T and B lymphocytes by the secretion of a number of pro-inflammatory cytokines; moreover cell trafficking at epithelium level is mainly coordinated by adhesion molecules expression [5–9]. One of the major cell types involved in inflammatory events associated with COPD is alveolar macrophages, which are able to produce several chemotactic factors [10,11]. The high production of chemo-attractants results in increased lung neutrophil and lymphocyte infiltration which in turn produce pro-inflammatory cytokines that contribute to the development and progression of the lung disease. The chronicity of COPD systemic inflammation is sustained by an increased production of several pro-inflammatory cytokines at both serum and airway levels. Indeed, C-reactive protein (CRP), fibrinogen, IL1 β , TNF α , MCP1, IL8, IL6 have been associated with disease progression and exacerbation [12–14], whilst an inverse correlation between anti-inflammatory cytokine IL-10 and COPD has been demonstrated.

The development of chronic systemic inflammation in COPD has not yet been fully understood. One possible mechanism may be due to the spill-over of pro-inflammatory factors and cells (neutrophils, lymphocytes) from lung to peripheral blood [15]. The contribution of lung in induction of this process is probably due to the increased permeability of pulmonary vessels in COPD, which contributes to the emission of pro-inflammatory. Another hypothesis supports the proposition that an enhanced expression of granulocyte-macrophage colony-stimulating factor and IL-6 in COPD plays an important

role, as these mediators stimulate neutrophils release from the bone marrow causing an increased neutrophil amount in the peripheral blood [16,17]. However, it is notable that systemic inflammation is heterogeneously distributed over COPD patients [11] and that comorbidities may be related to age rather than disease severity [18]. Therefore, the precise mechanism is still not fully understood.

Airway epithelium represents a central site for the mechanisms involved in the complex interaction between environmental triggers, airway inflammation and metabolic pathways [12–14,19,20]. Regarding peripheral organs, muscle, liver and adipose tissues are a source of a wide range of inflammatory mediators that have systemic effects when released in the systemic compartment.

The systemic inflammatory state has also been attributed to metabolic impairments in COPD patients [2,10,11]. Recent clinical investigations have highlighted the role of metabolic syndrome biomarkers to predict lung function impairment [16]. Naaved *et al.* found that dyslipidemia, elevated heart rate, increased insulin resistance and leptin levels were independent risk factors of greater susceptibility to lung function impairment within six months of World Trade Center irritant exposure, whereas elevated amylin was protective [21]. The authors suggest that metabolic syndrome biomarkers expressed soon after exposure to World Trade Center dust predicted FEV1 decline, and the systemic inflammation produced by metabolic syndrome impacted on progression to abnormal lung function in a longitudinally followed cohort [21]. Through these observations, a growing interest has been focused on the interaction between metabolic disorders and COPD; however, it remains still to be elucidated which biological pathway is mainly involved.

The potential interaction between abnormal adipose tissue and lung function impairment may be ascribed to systemic inflammation, thus providing new insight into the pathogenesis and reversibility of systemic involvement of COPD [22]. Accordingly, a link between adipose tissues and circulating concentrations of TNF α , IL6, leptin and adiponectin that play an important part in metabolic changes associated with COPD and in lung function decrease has been demonstrated [23].

In particular, the importance of adiponectin expression in lung function and COPD severity has been recently highlighted. This review will focus on the mechanisms by which the adiponectin system is a potentially attractive marker for systemic involvement in COPD.

2. Adiponectin and Adipose Tissue

A key role for systemic inflammation in development of both metabolic disorders and lung function impairment has been recently reported and, therefore, scientific interest has been focused on adipocyte-derived cytokines including adiponectin. Adipose tissue is a highly dynamic endocrine organ that synthesizes and secretes a variety of proteins known as “adipokines” involved in several metabolic processes such as immunity, insulin resistance, lipid and glucose metabolisms and inflammation [21–25].

Adiponectin is known to exert anti-inflammatory effects. It is a proteic hormone synthesized and secreted by adipose tissue as a 30 kDa monomer that, due to post-translational modifications, forms characteristic homomultimers. In fact, adiponectin assembles into several oligomeric multimers including trimers, known as low molecular weight (LMW); hexamers, known as medium molecular weight (MMW) and higher-molecular weight (HMW) multimeric complexes [26]. Growing evidence associates the oligomerization process with multiple biological activities of adiponectin since HMW are considered

the most biologically active isoforms [26,27]. Adiponectin structurally belongs to the complement 1q family and is found at high concentrations ($>0.01\%$ of the total protein) in serum of healthy individuals [28]. In humans, the gene encoding adiponectin (ACDC) is located on chromosome 3q27; single-nucleotide polymorphisms (SNPs) and haplotypes in ACDC gene have been associated with obesity as well as with metabolic syndrome and cardiovascular diseases [29–32]. Two receptors (AdipoR1 and AdipoR2), ubiquitous expressed in several organs, including lung, tissues and cell lines, mediate adiponectin effects [26,33,34]. Downstream of these two receptors, the biological effects of adiponectin are mediated by different signal pathways involving the following molecules: AMPK, ERK, AKT and P38 [33,35]. In particular, it is reported that AdipoR1 is mainly implicated in the metabolic functions of adiponectin, whereas AdipoR2 is more involved in anti-inflammatory and anti stress-oxidative activities [33,36,37].

In obesity, systemic concentrations of total adiponectin and its different isoforms are disproportionately reduced [38]. Moreover, the proportion of HMW isoforms to total adiponectin is lower among obese individuals than healthy controls [38]. One explanation for this surprising finding is that adipose tissue in the obese experiences localized hypoxia that inhibits the expression of adiponectin [38,39]. The hypoxia-induced necrosis of adipocytes attracts activated macrophages that collect to form functional syncytia surrounding the necrotizing adipocytes. These syncytia produce TNF α and IL6 which may inhibit the local production of adiponectin by the adipose tissue [24,40]. Interestingly, there are marked sexual differences of the distribution of adiponectin and compared to men, women have higher circulating levels of HMW isoforms, despite greater levels of overall adiposity. Moreover, postmenopausal women have higher proportions of HMW than premenopausal women, with a negative association of circulating concentrations of total and HMW adiponectin with sex steroids [41,42].

3. Adiponectin, Metabolic Disorders and COPD

3.1. Adiponectin Role in Inflammation

Adiponectin is important in energy homeostasis, regulating both glucose and lipid metabolism. In humans, down regulation of adiponectin and its receptors is associated with obesity, metabolic syndrome, insulin resistance, hyperinsulinemia and type 2 diabetes, as well as with cardiovascular diseases [26,31]. Moreover, adiponectin seems implicated in the development and progression of several local and systemic inflammatory processes.

In fact, it has been recently outlined that adiponectin could play an important role in anti-inflammatory responses in several tissues and cell cultures such as pancreatic beta cells and endothelial cells [43–45]. A protective anti-inflammatory role of HMW oligomers has been demonstrated both *in vivo* and *in vitro* studies [26,36,46,47]. Research findings indicate that adiponectin exerts its anti-inflammatory properties by inhibiting several pro-inflammatory mediators (TNF α , IL6, endothelial adhesion molecules ICAM-1 and nuclear factor- κ B) [48,49] and promoting anti-inflammatory mediators (IL10 and IL1 receptor antagonist) [50]. *In vitro* studies show the additional down-regulation of the inflammatory infectious state of adiponectin while binding bacterial lipopolysaccharides [51]. In addition, HMW oligomers seem to improve insulin sensitivity, suppress apoptosis in endothelial cells and are inversely correlated to cardiovascular events and to the severity of coronary artery disease [46]. The role of adiponectin in

energy metabolism has been widely studied, while little is known about its role in inflammatory processes of lung [24,52]. In fact, human and murine studies are still inconclusive and both pro-inflammatory and anti-inflammatory lung adiponectin properties have been hypothesized.

3.2. Evidence for a Role of Adiponectin in COPD: Human Studies

Human studies have demonstrated a significant increase of serum adiponectin levels in COPD and a direct correlation to the severity of the disease [24,52,53]. Indeed, relationship between adiponectin concentrations and accelerated decline in lung functions has been reported [54–56]. Moreover, serum adiponectin levels are not significantly influenced by smoking status in COPD [54]. More recently, Carolan *et al.* reported adiponectin contribution also in development of emphysema [57].

Serum adiponectin levels represent a significant diagnostic and prognostic marker of COPD but the real biological effects of adiponectin and of its oligomers on human lung and even less in lung diseases are not fully clear [54–56]. Recently, it has demonstrated that the oligomerization pattern of adiponectin is altered in COPD; in particular the higher levels of adiponectin are associated with a specific increase of HMW, the most biologically active isoforms [58]. Daniele *et al.* found no detectable TNF α values in normal subjects and in COPD patients suggesting that the high levels of adiponectin and HMW could be involved in reducing the increase of circulating levels of this pro-inflammatory cytokine [58].

Emerging evidence suggests adiponectin as an immunomodulator and tumor adipokine since it is implicated in the pathogenesis and prognosis of different cancers, including lung cancer [58,59]. In fact, it was demonstrated that both AdipoRs are expressed in COPD and tumor lung [33,59]; moreover a recent study demonstrated a higher expression of AdipoR1 than AdipoR2 in lung tissues from COPD and non small cell lung cancer (NSCLC) suggesting a specific signaling pathway of adiponectin in this disease [60]. In addition, the down-regulation of AdipoR2 could be responsible for the worsening of the inflammatory state in COPD and related to the development of lung NSCLC cancer [60]. Recent studies furthermore indicate an association between genetic variants in adiponectin gene and COPD as well as in NSCLC [61,62]. Recently, Ghafar *et al.* suggested that adiponectin could suppress NSCLC cancer cell development by AdipoR2 while AdipoR1 may have favorable prognostic significance [63]. The molecular mechanism underlying adiponectin effects on normal cells remains not yet completely clarified. A recent *in vitro* study evaluated the effects of adiponectin on A549 cells, a model of alveolar epithelium showing that, in a time and dose-dependent manner, it decreases cell viability and increases apoptosis through ERK1/2 and AKT [36].

3.3. Anti-Inflammatory Role in Lung and COPD (in Vitro and Vivo Studies)

The secretion of several inflammatory molecules, such as IL1 β and TNF α , from different cell types is increased by reactive oxygen species. In particular, TNF α and IL1 β induce both macrophages to secrete matrix metalloproteinase-9, and bronchial epithelial cells to produce extracellular matrix can increase gene expression of glycoproteins. Recent data have revealed the anti-inflammatory role in the lungs of genetically-induced adiponectin deficient mice (Adiponectin^{−/−}), showing higher expression of TNF α in alveolar macrophages and abnormal alveolarization, resembling an emphysema-like phenotype, reversible with adiponectin supplementation [49,64]. The anti-inflammatory properties of adiponectin are further supported by extrapulmonary inflammation, vascular endothelial dysfunction

and some other comorbidities (osteoporosis and cachexia) shown in the same mouse model [49,64]. Furthermore, Summer *et al.* hypothesized a protective role of adiponectin on the lungs through inhibition of alveolar macrophage function and vascular homeostasis regulation [49,64]. Moreover, Nigro *et al.* [36] observed that, in cells exposed to TNF α and/or IL1 β , two potent lung inflammatory cytokines, adiponectin, in dose- and time-dependent manner, reduce cytotoxic effects of TNF α and IL1 β improving cell viability and decreasing apoptosis. In the same paper, it was demonstrated that adiponectin inhibits NF- κ B nuclear trans-activation and induces the expression of the anti-inflammatory IL10 cytokine via ERK1/2 and AKT through the mediation of AdipoR1 [36].

3.4. Pro-Inflammatory Role in Lung and COPD (in Vitro and Vivo Studies)

On the other hand, it was reported that adiponectin may induce inflammatory activation in macrophages and in A549 cells [65]; moreover, in adiponectin-deficient mice, it was demonstrated that adiponectin could play an important pro-inflammatory role in tobacco smoke-induced COPD [66].

However, why adiponectin has been found to exhibit pro-inflammatory effects under certain conditions needs to be investigated.

In conclusion, although the biological meaning of adiponectin modulation remains to be clarified, a protective role of adiponectin and its oligomeric isoforms in lung inflammation, through AdipoR1 receptor has been widely demonstrated. It is not completely clear how modulation of adiponectin, may be helpful in COPD prevention and treatment. However, most evidence demonstrate that adiponectin represents a useful diagnostic and prognostic biomarker in COPD. Therefore, further studies are needed to fully elucidate the complexity of adiponectin system effects in the lungs.

4. Conclusions

In this review, the role of adiponectin system in lung disorders has been analyzed. Investigations on adiponectin systemic production and epithelial cell receptors at lung level have provided new insight in COPD pathophysiology. Serum levels of adiponectin represent a significant diagnostic and prognostic marker for COPD disease. The molecular mechanisms through which adiponectin mediates its effects in the lungs are not clearly defined; however, AdipoRs expression on lung epithelial cells of COPD patients strengthens the hypothesis of its role in pathophysiological conditions of the lungs.

Altogether, the reported evidence indicate that adiponectin and its oligomerization state are involved in lung diseases and that its increased levels are mainly due to HMW oligomers. The observations reported suggest that total levels of adiponectin, HMW oligomers and AdipoRs could represent useful complementary criteria to improve therapeutic and prognostic strategies for diseases that involve lung impairment. Adiponectin seems to exert a direct protective role on lung epithelial A549 cells exhibiting anti proliferative and anti-inflammatory effects. Furthermore, *in vitro* studies demonstrated that adiponectin protects A549 lung cells against cytotoxicity induced by TNF α - or IL-1 β .

Better understanding of mechanisms underlying systemic inflammation and extrapulmonary comorbidities in COPD will help identification of new targets for both diagnostic and therapeutic approaches. Adiponectin appears to be an attractive biomarker in COPD and represents a promising disease indicator with potential implications in COPD therapeutical management.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Vestbo, J.; Hurd, S.S.; Agustí, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M.; *et al.* Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am. J. Respir. Crit. Care Med.* **2013**, *187*, 347–365.
2. Nussbaumer-Ochsner, Y.; Rabe Klaus, F. Systemic manifestations of COPD. *Chest* **2011**, *139*, 165–173.
3. Corbi, G.M.; Carbone, S.; Ziccardi, P.; Giugliano, G.; Marfella, R.; Nappo, F.; Paolisso, G.; Esposito, K.; Giugliano, D. FFAs and QT intervals in obese women with visceral adiposity: Effects of sustained weight loss over 1 year. *J. Clin. Endocrinol. Metab.* **2002**, *87*, 2080–2083.
4. Corbi, G.; Bianco, A.; Turchiarelli, V.; Cellurale, M.; Fatica, F.; Daniele, A.; Mazzarella, G.; Ferrara, N. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: Focus on sirtuins. *Int. J. Mol. Sci.* **2013**, *14*, 12696–12713.
5. Whiteman, S.C.; Bianco, A.; Knight, R.A.; Spiteri, M.A. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. *J. Biol. Chem.* **2003**, *278*, 11954–11961.
6. De Laurentiis, G.; Paris, D.; Melck, D.; Montuschi, P.; Maniscalco, M.; Bianco, A.; Sofia, M.; Motta, A. Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate. *J. Proteome Res.* **2013**, *12*, 1502–1511.
7. Bianco, A.; Whiteman, S.C.; Sethi, S.K.; Allen, J.T.; Knight, R.A.; Spiteri, M.A. Expression of intercellular adhesion molecule-1 (ICAM-1) in nasal epithelial cells of atopic subjects: A mechanism for increased rhinovirus infection? *Clin. Exp. Immunol.* **2000**, *121*, 339–345.
8. Bianco, A.; Sethi, S.K.; Allen, J.T.; Knight, R.A.; Spiteri, M.A. Th2 cytokines exert a dominant influence on epithelial cell expression of the major group human rhinovirus receptor, ICAM-1. *Eur. Respir. J.* **1998**, *12*, 619–626.
9. Sethi, S.K.; Bianco, A.; Allen, J.T.; Knight, R.A.; Spiteri, M.A. Interferon-gamma (IFN-gamma) down-regulates the rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) on human airway epithelial cells. *Clin. Exp. Immunol.* **1997**, *110*, 362–369.
10. Corsonello, A.; Antonelli Incalzi, R.; Pistelli, R.; Pedone, C.; Bustacchini, S.; Lattanzio, F. Comorbidities of chronic obstructive pulmonary disease. *Curr. Opin. Pulm. Med.* **2011**, *17*, S21–S28.
11. Agustí, A. Systemic effects of chronic obstructive pulmonary disease: What we know and what we don't know (but should). *Proc. Am. Thorac. Soc.* **2007**, *4*, 522–525.
12. Mazzarella, G.; Ferraraccio, F.; Prati, M.V.; Annunziata, S.; Bianco, A.; Mezzogiorno, A.; Liguori, G.; Angelillo, I.F.; Cazzola, M. Effects of diesel exhaust particles on human lung epithelial cells: An *in vitro* study. *Respir. Med.* **2007**, *101*, 1155–1162.

13. Mazzearella, G.; Esposito, V.; Bianco, A.; Ferraraccio, F.; Prati, M.V.; Lucariello, A.; Manente, L.; Mezzogiorno, A.; de Luca, A. Inflammatory effects on human lung epithelial cells after exposure to diesel exhaust micron sub particles (PM_{1.0}) and pollen allergens. *Environ. Pollut.* **2012**, *161*, 64–69.
14. Esposito, V.; Lucariello, A.; Savarese, L.; Cinelli, M.P.; Ferraraccio, F.; Bianco, A.; de Luca, A.; Mazzearella, G. Morphology changes in human lung epithelial cells after exposure to diesel exhaust micron sub particles (PM_{1.0}) and pollen allergens. *Environ. Pollut.* **2012**, *171*, 162–167.
15. Barnes, P.J.; Celli, B.R. Systemic manifestations and comorbidities of COPD. *Eur. Respir. J.* **2009**, *33*, 1165–1185.
16. Laveneziana, P.; Palange, P.; ERS Research Seminar Faculty. Physical activity, nutritional status and systemic inflammation in COPD. *Eur. Respir. J.* **2012**, *40*, 522–529.
17. Vaguliene, N.; Zemaitis, M.; Lavinskiene, S.; Miliauskas, S.; Sakalauskas, R. Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease. *BMC Immunol.* **2013**, *14*, 36.
18. Burgel, P.R.; Paillasseur, J.L.; Caillaud, D.; Tillie-Leblond, I.; Chanez, P.; Escamillaf, R.; Court-Fortune, I.; Perez, T.; Carré, P.; Roche, N. Clinical COPD phenotypes: A novel approach using principal component and cluster analyses. *Eur. Respir. J.* **2010**, *36*, 531–539.
19. Van den Bemt, L.; van Wayenburg, C.A.; Smeele, I.J.; Schermer, T.R. Obesity in patients with COPD, an undervalued problem? *Thorax* **2009**, *64*, 640.
20. Floreani, A.A.; Wyatt, T.A.; Stoner, J.; Sanderson, S.D.; Thompson, E.G.; Allen-Gipson, D.; Heires, A.J. Smoke and C5a induce airway epithelial intercellular adhesion molecule-1 and cell adhesion. *Am. J. Respir. Cell Mol. Biol.* **2003**, *29*, 472–482.
21. Yang, Y.M.; Sun, T.Y.; Liu, X.M. The role of serum leptin and tumor necrosis factor-alpha in malnutrition of male chronic obstructive pulmonary disease patients. *Chin. Med. J.* **2006**, *119*, 628–633.
22. Naveed, B.; Weiden, M.D.; Kwon, S.; Gracely, E.J.; Comfort, A.L.; Ferrier, N.; Kasturiarachchi, K.J.; Cohen, H.W.; Aldrich, T.K.; Rom, W.N.; *et al.* Metabolic syndrome biomarkers predict lung function impairment: A nested case-control study. *Am. J. Respir. Crit. Care Med.* **2012**, *185*, 392–399.
23. Franssen, F.M.; O'Donnell, D.E.; Goossens, G.H.; Blaak, E.E.; Schols, A.M. Obesity and the lung: 5. Obesity and COPD. *Thorax* **2008**, *63*, 1110–1117.
24. Kirdar, S.; Serter, M.; Ceylan, E.; Sener, A.G.; Kavak, T.; Karadağ, F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. *Scand. J. Clin. Lab. Investig.* **2009**, *69*, 219–224.
25. Tkacova, R. Systemic inflammation in chronic obstructive pulmonary disease: May adipose tissue play a role? Review of the literature and future perspectives. *Mediat. Inflamm.* **2010**, *2010*, 1–12.
26. Pajvani, U.B.; Du, X.; Combs, T.P.; Berg, A.H.; Rajala, M.W.; Schulthess, T.; Engel, J.; Brownlee, M.; Scherer, P.E. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. *J. Biol. Chem.* **2003**, *278*, 9073–9085.
27. Kadowaki, T.; Yamauchi, T. Adiponectin and adiponectin receptors. *Endocr. Rev.* **2005**, *26*, 439–451.

28. Daniele, A.; de Rosa, A.; de Cristofaro, M.; Monaco, M.L.; Masullo, M.; Porcile, C.; Capasso, M.; Tedeschi, G.; Oriani, G.; di Costanzo, A. Decreased concentration of adiponectin together with a selective reduction of its high molecular weight oligomers is involved in metabolic complications of myotonic dystrophy type 1. *Eur. J. Endocrinol.* **2011**, *165*, 969–975.
29. Landbo, C.; Prescott, E.; Lange, P.; Vestbo, J.; Almdal, T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **1999**, *160*, 1856–1861.
30. Daniele, A.; Cammarata, R.; Pasanisi, F.; Finelli, C.; Salvatori, G.; Calcagno, G.; Bracale, R.; Labruna, G.; Nardelli, C.; Buono, P.; *et al.* Molecular analysis of the adiponectin gene in severely obese patients from southern Italy. *Ann. Nutr. Metab.* **2008**, *53*, 155–161.
31. Daniele, A.; Cammarata, R.; Masullo, M.; Nerone, G.; Finamore, F.; D’Andrea, M.; Pilla, F.; Oriani, G. Analysis of adiponectin gene and comparison of its expression in two different pig breeds. *Obesity* **2008**, *16*, 1869–1874.
32. Gable, D.R.; Matin, J.; Whittall, R.; Cakmak, H.; Li, K.W.; Cooper, J.; Miller, G.J.; Humphries, S.E.; HIFMECH investigators. Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects. *Ann. Hum. Genet.* **2007**, *71*, 453–466.
33. Miller, M.; Cho, J.Y.; Pham, A.; Ramsdell, J.; Broide, D.H. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. *J. Immunol.* **2009**, *182*, 684–691.
34. Yamauchi, T.; Nio, Y.; Maki, T.; Kobayashi, M.; Takazawa, T.; Iwabu, M.; Okada-Iwabu, M.; Kawamoto, S.; Kubota, N.; Kubota, T.; *et al.* Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. *Nat. Med.* **2007**, *13*, 332–339.
35. De Rosa, A.; Monaco, M.L.; Nigro, E.; Scudiero, O.; D’Andrea, M.; Pilla, F.; Oriani, G.; Daniele, A. Tissue-specific downregulation of the adiponectin “system”: Possible implications for fat accumulation tendency in the pig. *Domest. Anim. Endocrinol.* **2013**, *44*, 131–138.
36. Nigro, E.; Scudiero, O.; Sarnataro, D.; Mazzarella, G.; Sofia, M.; Bianco, A.; Daniele, A. Adiponectin affects lung epithelial A549 cell viability counteracting TNF α and IL-1 β toxicity through AdipoR1. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 1145–1153.
37. Buechler, C.; Wanninger, J.; Neumeier, M. Adiponectin receptor binding proteins—Recent advances in elucidating adiponectin signalling pathways. *FEBS Lett.* **2010**, *584*, 4280–4286.
38. De Rosa, A.; Monaco, M.L.; Capasso, M.; Forestieri, P.; Pilone, V.; Nardelli, C.; Buono, P.; Daniele, A. Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects. *Eur. J. Endocrinol.* **2013**, *169*, 37–43.
39. Baldi, S.; Aquilani, R.; Pinna, G.D.; Poggi, P.; De Martini, A.; Bruschi, C. Fat-free mass change after nutritional rehabilitation in weight losing COPD: Role of insulin, C-reactive protein and tissue hypoxia. *Int. J. Chronic Obstr. Pulm. Dis.* **2010**, *5*, 29–39.
40. Lang, K.; Ratke, J. Leptin and Adiponectin: New players in the field of tumor cell and leukocyte migration. *Cell Commun. Signal.* **2009**, *7*, 27.
41. Nishizawa, H.; Shimomura, I.; Kishida, K.; Maeda, N.; Kuriyama, H.; Nagaretani, H.; Matsuda, M.; Kondo, H.; Furuyama, N.; Kihara, S.; *et al.* Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. *Diabetes* **2002**, *51*, 2734–2741.

42. Leung, K.C.; Xu, A.; Craig, M.E.; Martin, A.; Lam, K.S.; O'Sullivan, A.J. Adiponectin isoform distribution in women—Relationship to female sex steroids and insulin sensitivity. *Metabolism* **2009**, *58*, 239–245.
43. Tomizawa, A.; Hattori, Y.; Kasai, K.; Nakano, Y. Adiponectin induces NF-kappaB activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells: Globular adiponectin vs. high molecular weight adiponectin. *Diabetes Vasc. Dis. Res.* **2008**, *5*, 123–127.
44. Wijesekara, N.; Krishnamurthy, M.; Bhattacharjee, A.; Suhail, A.; Sweeney, G.; Wheeler, M.B. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. *J. Biol. Chem.* **2010**, *285*, 33623–33631.
45. Zhao, H.Y.; Zhao, M.; Yi, T.N.; Zhang, J. Globular adiponectin protects human umbilical vein endothelial cells against apoptosis through adiponectin receptor 1/adenosine monophosphate-activated protein kinase pathway. *Chin. Med. J.* **2011**, *124*, 2540–2547.
46. Bråkenhielm, E.; Veitonmäki, N.; Cao, R.; Kihara, S.; Matsuzawa, Y.; Zhivotovsky, B.; Funahashi, T.; Cao, Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 2476–2481.
47. Grossmann, M.E.; Nkhata, K.J.; Mizuno, N.K.; Ray, A.; Cleary, M.P. Effects of adiponectin on breast cancer cell growth and signaling. *Br. J. Cancer* **2008**, *98*, 370–379.
48. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; *et al.* Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. *Circulation* **1999**, *100*, 2473–2476.
49. Ajuwon, K.M.; Spurlock, M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2005**, *288*, R1220–R1225.
50. Wolf, A.M.; Wolf, D.; Rumpold, H.; Enrich, B.; Tilg, H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. *Biochem. Biophys. Res. Commun.* **2004**, *323*, 630–635.
51. Peake, P.W.; Shen, Y.; Campbell, L.V.; Charlesworth, J.A. Human adiponectin binds to bacterial lipopolysaccharide. *Biochem. Biophys. Res. Commun.* **2006**, *341*, 108–115.
52. Takeda, Y.; Nakanishi, K.; Tachibana, I.; Kumanogoh, A. Adiponectin: A novel link between Adipocytes and COPD. *Vitam. Horm.* **2012**, *90*, 419–435.
53. Summer, R.; Little, F.F.; Ouchi, N.; Takemura, Y.; Aprahamian, T.; Dwyer, D.; Fitzsimmons, K.; Suki, B.; Parameswaran, H.; Fine, A.; *et al.* Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2008**, *294*, L1035–L1042.
54. Chan, K.H.; Yeung, S.C.; Yao, T.J.; Ip, M.S.; Cheung, A.H.; Chan-Yeung, M.M.; Mak, J.C.; COPD Study Group of the Hong Kong Thoracic Society. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. *Int. J. Tuberc. Lung Dis.* **2010**, *14*, 1193–1200.
55. Tomoda, K.; Yoshikawa, M.; Itoh, T.; Tamaki, S.; Fukuoka, A.; Komeda, K.; Kimura, H. Elevated circulating plasma adiponectin in underweight patients with COPD. *Chest* **2007**, *132*, 135–140.

56. Yoon, H.I.; Li, Y.; Man, S.F.; Tashkin, D.; Wise, R.A.; Connett, J.E.; Anthonisen, N.A.; Churg, A.; Wright, J.L.; Sin, D.D. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. *Chest* **2012**, *142*, 893–899.
57. Carolan, B.J.; Kim, Y.I.; Williams, A.A.; Kechris, K.; Lutz, S.; Reisdorph, N.; Bowler R.P. The association of Adiponectin with CT phenotypes in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **2013**, *188*, 561–566.
58. Daniele, A.; de Rosa, A.; Nigro, E.; Scudiero, O.; Capasso, M.; Masullo, M.; de Laurentiis, G.; Oriani, G.; Sofia, M.; Bianco, A. Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease. *Int. J. Biochem. Cell Biol.* **2012**, *44*, 563–569.
59. Ntikoudi, E.; Kiagia, M.; Boura P.; Syrigos, K.N. Hormones of adipose tissue and their biologic role in lung cancer. *Cancer Treat. Rev.* **2013**, doi: 10.1016/j.ctrv.2013.06.005.
60. Petridou, E.T.; Mitsiades, N.; Gialamas, S.; Angelopoulos, M.; Skalkidou, A.; Dessypris, N.; Hsi, A.; Lazaris, N.; Polyzos, A.; Syrigos, C.; *et al.* Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: Two case-control studies. *Oncology* **2007**, *73*, 261–269.
61. Cui, E.; Deng, A.; Wang, X.; Wang, B.; Mao, W.; Feng, X.R.; Hua, F. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. *Biochem. Cell Biol.* **2011**, *89*, 308–313.
62. Yuan, Y.; Jiang, H.; Kuang, J.; Hou, X.; Feng, Y.; Su, Z. Genetic variations in ADIPOQ gene are associated with chronic obstructive pulmonary disease. *PLoS One* **2012**, *7*, e50848.
63. Abdul-Ghafar, J.; Oh, S.S.; Park, S.M.; Wairagu, P.; Lee, S.N.; Jeong, Y.; Eom, M.; Yong, S.J.; Jung, S.H. Expression of adiponectin receptor 1 is indicative of favorable prognosis in non-small cell lung carcinoma. *Tohoku J. Exp. Med.* **2013**, *229*, 153–162.
64. Summer, R.; Fiack, C.A.; Ikeda, Y.; Sato, K.; Dwyer, D.; Ouchi, N.; Fine, A.; Farber, H.W.; Walsh, K. Adiponectin deficiency: A model of pulmonary hypertension associated with pulmonary vascular disease. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2009**, *297*, L432–L438.
65. Cheng, X.; Folco, E.J.; Shimizu, K.; Libby, P. Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. *J. Biol. Chem.* **2012**, *287*, 36896–36904.
66. Miller, M.; Pham, A.; Cho, J.Y.; Rosenthal, P.; Broide, D.H. Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2010**, *299*, L834–L842.